Alcobra Ltd (ADHD) was Downgraded by Piper Jaffray to ” Neutral”. Earlier the firm had a rating of “Overweight ” on the company shares. Piper Jaffray advised their investors in a research report released on Sep 30, 2016.
Many Wall Street Analysts have commented on Alcobra Ltd. Alcobra Ltd was Downgraded by Cantor Fitzgerald to ” Hold” on Sep 29, 2016. Shares were Downgraded by WBB Securities on Sep 12, 2016 to ” Sell” and Lowered the Price Target to $ 4 from a previous price target of $5 .Barclays Initiated Alcobra Ltd on Aug 1, 2016 to “Equal Weight”, Price Target of the shares are set at $8.
Alcobra Ltd opened for trading at $4.59 and hit $4.66 on the upside on Tuesday, eventually ending the session at $4.61, with a gain of 0.44% or 0.02 points. The heightened volatility saw the trading volume jump to 61,752 shares. Company has a market cap of $127 M.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug MG01CI to treat Attention Deficit Hyperactivity Disorder (ADHD) a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs higher divorce rates lower levels of socioeconomic attainment lower academic achievement unemployment and work place deficits increased risks for motor vehicle accidents greater likelihood of additional psychiatric disorders increased criminal activity and incarceration and higher rates of substance use and abuse. MG01CI product has completed phase two studies.